CAI

Caris Life Sciences is a precision-oncology / AI-TechBio company that profiles cancer at the molecular level (MI Profile tissue platform, blood-based Caris Assure, and the FDA-approved MI Cancer Seek companion diagnostic). It has built what it believes is one of the largest multi-modal clinico-genomic datasets in oncology, with over 1,000,000 cases profiled, and partners with blue-chip biopharma (Moderna, AbbVie, Merck KGaA, Genentech). The growth is exceptional: FY2025 revenue nearly doubled, up 97.0% to $812M, with clinical case volume rising to 199,300 from 162,850, driven by the 2025 broad launch of MI Cancer Seek and ramping Caris Assure adoption.

The profitability trajectory is inflecting fast. Operating income turned positive at $45.1M (a 117.5% swing), and the net loss narrowed dramatically to -$68.1M from -$282M the prior year — a clear path toward GAAP breakeven as volumes scale against a largely fixed cost base. Operating cash flow was already positive at $83.2M (up 133.9%), an unusual and encouraging sign for a high-growth diagnostics company. Following its June 2025 IPO the balance sheet is strong: cash surged to $796M, current assets are $998M against just $127M of current liabilities, and liabilities/equity sits at a healthy 0.95x, giving ample runway to fund growth without near-term dilution pressure.